人工智能评估粪便质量通过智能手机应用指导肝性脑病管理
研究评估Dieta应用基于人工智能的Bristol粪便量表(AI-BSS)在肝硬化患者中的可接受性及对乳果糖剂量调整的指导作用。对照组13例和肝硬化患者33例使用应用并记录自我Bristol评分(self-BSS)与AI-BSS,部分患者(n=12)在阻断AI沟通后复测。多数受试者对应用感到舒适,随着使用时间延长,self-BSS与AI-BSS及乳果糖剂量与AI-BSS的相关性增加,AI-BSS沟通改善了对自我评分的洞察力。
要点
- Dieta应用可接受性良好,多数受试者感到舒适。
- 随应用使用时间延长,自我Bristol评分与AI-Bristol评分及乳果糖剂量与AI-Bristol评分的相关性增加。
- AI-Bristol评分沟通改善了对自我Bristol评分的洞察力。
核心结论
- Dieta应用评估粪便AI特征是可接受的,并增加了肝硬化患者对乳果糖剂量和Bristol评分的洞察力。
研究设计与样本
- 初始纳入对照组(N=13)和肝硬化患者(n=33,使用或不使用乳果糖),在应用上培训后输入自我Bristol评分(self-BSS)并获取AI-Bristol评分(AI-BSS)反馈,追踪乳果糖剂量变化;其中一部分(n=12)在阻断AI沟通后复测。
主要发现
- 多数受试者对应用感到舒适。
- 随着应用使用,self-BSS与AI-BSS及乳果糖剂量与AI-BSS的相关性增加。
- AI-BSS沟通随时间改善了对self-BSS的洞察力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls (N = 13) and cirrhosis patients on lactulose/not on lactulose (n = 33) were trained on the app. They entered self-reported BSS (self-BSS) with AI-BSS communicated. Lactulose dose changes were tracked. A subset (n = 12) was retested with AI communication blocked. Most subjects were comfortable with the app. Self/AI-BSS and lactulose dose/AI-BSS correlation increased with app use. AI-BSS communications improved insight into self-BSS over time. Dieta app to gauge stool AI characteristics was acceptable and increased insight into lactulose dose and BSS in cirrhosis.
引用
- Fagan A, Gallagher ML, Mousel T, et al. Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App. Am J Gastroenterol. 2023. PMID: 38153339. doi:10.14309/ajg.0000000000002646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。